|2011||Acquisition of Q-Med, a Swedish company specialized in aesthetic & corrective solutions.
Emervel (dermal filler range) launch in Europe and Latin America.
Launch of Cetaphil Restoraderm.
Plant extensions in France and Canada.
|2010||Differin Lotion 0.1% (acne) launch in the United States.
Galderma hits the 1 billion mark in sales.
|2009||Launch of Azzalure (glabellar lines) and Oracea in Europe.
Vectical (psoriasis) launch in the United-States. Oracea
|2008||Epiduo (acne) launch.
Acquisition of CollaGenex Pharmaceuticals and its product Oracea (rosacea).
Launch of Differin 0.1% in Japan. Differin
|2007||Licensing agreements for a botulinum toxin type A and Pliaglis (topical anesthetic).
Differin 0.3% launch. Pliaglis
|2006||Clobex Spray launch in the US.
Opening of the new R&D center in Sophia Antipolis, France.
|2005||Metrogel 1% (rosacea) launch in the United-States.
For the first time, Galderma ranks Number One in D class in its markets
(source: IMS Health, IMS dataview - D class - MAT Q3 2005 - 33 countries).
|2004||Opening of a new production site in Hortolandia, Brazil.
Clobex Shampoo launch in the United-States and acquisition of Tri-Luma.
|2003||Launch of Metvix in Germany and the UK and Clobex Lotion (inflammatory skin conditions) in the US.|
|2002||Licensing agreements for Tri-Luma (melasma or mask of pregnancy) and Pekiron (Loceryl Cream) in Japan.
First FDA approvals for pharmaceutical production in Montreal.
|2001||Licensing agreement for Metvix (precancerous skin lesions and skin cancer treatment).
Launch of Clindagel (anti-acne).
|2000||The Montreal production unit comes on stream.
Launch of Silkis (psoriasis) and acquisition of Capex Shampoo (seborrheic dermatitis).
|1999||Acquisition of Loceryl (fungal nail infections), developed by Laboratoires Roche, together with the Scandinavian dermatology portfolio developed by Nycomed.|
|1998||Inauguration of a new R&D facility in Princeton, New Jersey, USA.
Acquisition in Brazil of Darrow’s dermatology portfolio.
|1997||Acquisition of Basotherm, a subsidiary of Boehringer.|
|1996||Acquisition of a plant belonging to Wyeth-Ayerts in Montreal, Canada, to develop a state-of-the-art manufacturing plant.|
|1995||Launch of anti-acne treatment Differin, Galderma’s first home-grown dermatology product.|
|1994||Galderma inaugurates its wholly-owned production plant in Alby-sur-Chéran, near Annecy in the French Alps.|
|1993||Acquisition of MetroGel / Rozex to include rosacea treatments in the product portfolio.|
|1989||Global organization implemented and new affiliates opened in Canada, Germany, Spain and the United Kingdom.|
|1988||Galderma progressively takes over Alcon’s dermatology business, allowing it to focus exclusively on ophthalmology.|
|1986||Galderma’s first affiliate opens for business in France, followed by a second in Italy. The International Dermatology Research Center focuses its efforts on prescription dermatology products.|
|1981||Nestlé and L'Oréal form a joint venture to become the world’s leading dermatology player. Galderma is born.|
|1979||L'Oréal creates its International Dermatology Research Center (CIRD) in Sophia-Antipolis, France, specializing in fundamental research into skin physiology.|
|1977||Nestlé acquires Alcon to strengthen its presence in the North American market.|
|1972||Acquisition of Owen by ophthalmology specialist Alcon, headquartered in Fort Worth, Texas.|
Creation of the Owen dermatology company in Dallas, Texas, USA.
|Senest oppdatert: 2018-10-24
©Galderma Nordic AB 2008-2018